Strontium ranelate 99% CAS NO 135459-87-9
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA).
On 13 May 2013, Servier released a Direct Healthcare Professional Communication which stated that new restrictions for the use of strontium ranelate are now in place, as randomised trials have shown an increased risk of myocardial infarction. Servier states that the use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture. The European Pharmacovigilance Risk Assessment Committee (PRAC) recommends restriction in the use of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which included data showing an increased risk of heart problems, including heart attacks. On 21 February 2014 the European Medicine Agency recommended that strontium ranelate remain available with restrictions relative to patients with existing heart disease.
Chinese Name: strontium ranelate
English Name: 2,2'-((5-Carboxy-4-(carboxymethyl) -3-cyanothiophen-2-yl) azanediyl) diacetic acid, distrontium salt
English alias: Ranelic Acid Strontium Salt; Strontium Ranelate; Strontium ranelate; CAS number: 135459-87-9
Molecular formula: C12H6N2O8SSr2
Molecular weight: 513.49000
Precise quality: 513.79600
Appearance and properties: crystalline solids
Boiling point: 778.8 C at 760 mmHg
Flash point: 424.8 x C
Signal word: warning
Hazard statement: H302 + H312 + H332
Cautionary statement: P280
Customs Code: 2942000000
Anti-osteoporosis drugs are mainly used to treat and prevent osteoporosis in postmenopausal women, significantly reducing the risk of vertebral and hip fractures.